Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Debt (2024 - 2025)

Apellis Pharmaceuticals (APLS) has 2 years of Total Debt data on record, last reported at $455.3 million in Q4 2025.

  • For Q4 2025, Total Debt rose 26.66% year-over-year to $455.3 million; the TTM value through Dec 2025 reached $455.3 million, up 26.66%, while the annual FY2025 figure was $455.3 million, 26.66% up from the prior year.
  • Total Debt reached $455.3 million in Q4 2025 per APLS's latest filing, roughly flat from $454.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $455.3 million in Q4 2025 and bottomed at $359.0 million in Q3 2024.